MX2020006188A - Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada. - Google Patents

Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada.

Info

Publication number
MX2020006188A
MX2020006188A MX2020006188A MX2020006188A MX2020006188A MX 2020006188 A MX2020006188 A MX 2020006188A MX 2020006188 A MX2020006188 A MX 2020006188A MX 2020006188 A MX2020006188 A MX 2020006188A MX 2020006188 A MX2020006188 A MX 2020006188A
Authority
MX
Mexico
Prior art keywords
strong acid
pharmaceutical compositions
composition
glycolide
lactide
Prior art date
Application number
MX2020006188A
Other languages
English (en)
Inventor
Yuhua Li
Andrew Guarino
Original Assignee
Foresee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Co Ltd filed Critical Foresee Pharmaceuticals Co Ltd
Publication of MX2020006188A publication Critical patent/MX2020006188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

La presente invención proporciona una composición polimérica biodegradable estabilizada útil como sistema de suministro de liberación controlada para agentes peptidicos. Las composiciones de la presente invención comprenden a) una sal de ácido fuerte y un ácido débil de un agonista o antagonista de LHRH; b) un polímero biodegradable de poli(lactida-co-glicolida), en donde la relación de lactida:glicolida del copolímero es de 50:50 a aproximadamente 100:0; y c) N-metil-2-pirrolidona (NMP), en donde la composición no contiene un exceso de ácido fuerte además del ácido fuerte usado para formar la sal del agonista o antagonista de LHRH. La composición, cuando se inyecta, puede proporcionar una liberación controlada de leuprolida durante un periodo de hasta 6 meses.
MX2020006188A 2017-12-18 2017-12-18 Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada. MX2020006188A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/066968 WO2019125358A1 (en) 2017-12-18 2017-12-18 Pharmaceutical compositions having a selected release duration

Publications (1)

Publication Number Publication Date
MX2020006188A true MX2020006188A (es) 2020-09-17

Family

ID=66993718

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006188A MX2020006188A (es) 2017-12-18 2017-12-18 Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada.

Country Status (12)

Country Link
US (2) US11717555B2 (es)
EP (1) EP3727421A4 (es)
JP (1) JP7223021B2 (es)
KR (2) KR102567885B1 (es)
AU (1) AU2017443632A1 (es)
BR (1) BR112020011774A2 (es)
CA (1) CA3084339A1 (es)
IL (1) IL275448A (es)
MX (1) MX2020006188A (es)
RU (1) RU2756514C1 (es)
SG (1) SG11202004525TA (es)
WO (1) WO2019125358A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117715637A (zh) * 2021-07-02 2024-03-15 逸达生物科技股份有限公司 注射用缓释制剂的制备方法
AU2022328761A1 (en) * 2021-08-16 2024-03-21 Foresee Pharmaceuticals Co., Ltd. Polymer depot compositions for sustained release delivery of vmat2 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
BR9507313A (pt) 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE10190041D2 (de) * 2000-01-11 2002-12-05 Roland Bodmeier Implantate, Partikel
ES2600554T3 (es) 2003-07-18 2017-02-09 Oakwood Laboratories L.L.C. Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
RU2427383C2 (ru) 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
EP2585092A1 (en) * 2010-06-24 2013-05-01 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability

Also Published As

Publication number Publication date
KR102522654B1 (ko) 2023-04-17
IL275448A (en) 2020-08-31
EP3727421A1 (en) 2020-10-28
US11717555B2 (en) 2023-08-08
WO2019125358A1 (en) 2019-06-27
EP3727421A4 (en) 2021-07-28
JP7223021B2 (ja) 2023-02-15
RU2756514C1 (ru) 2021-10-01
CA3084339A1 (en) 2019-06-27
US20230346877A1 (en) 2023-11-02
CN111511385A (zh) 2020-08-07
US20200390849A1 (en) 2020-12-17
SG11202004525TA (en) 2020-06-29
BR112020011774A2 (pt) 2020-11-17
KR20210005542A (ko) 2021-01-14
JP2021516253A (ja) 2021-07-01
AU2017443632A1 (en) 2020-07-30
NZ766167A (en) 2023-10-27
KR102567885B1 (ko) 2023-08-17
KR20230054755A (ko) 2023-04-25

Similar Documents

Publication Publication Date Title
HRP20180118T1 (hr) Injekcijski tekući pripravak koji sadrži buprenorfin
DK1786400T3 (da) Farmaceutiske sammensætning til tilförsel med kontrolleret frigivelse af biologisk aktive forbindelser
RS53205B (en) IMPLANTABLE PALIPERIDON FORMULATION
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
EA201401348A1 (ru) Технология приготовления имплантируемой формы палиперидона
EP3943098A3 (en) Compositions and methods for treating cancer
PE20060244A1 (es) Formulacion farmaceutica de deposito que contiene polietilenglicol de peso molecular menor a 600 daltones
ATE382337T1 (de) Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
AR113096A1 (es) Mezclas de composiciones biodegradables que modulan la cinética de liberación de al menos un ingrediente activo en la administración de fármacos
MY161930A (en) Antipsychotic injectable depot composition
MX2020006188A (es) Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada.
RU2012145811A (ru) Композиции и способы улучшенного удержания фармацевтической композиции на участке местного введения
MX371139B (es) Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.
BR112018002414A2 (pt) sistema de distribuição de polímero líquido para administração prolongada de fármacos
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
TN2009000476A1 (en) Slow release pharmaceutical composition made of microparticles
CO6190540A2 (es) Compuesto ceramico polimero y metodo
NZ731309A (en) Buprenorphine dosing regimens
MX2021001145A (es) Formulación de liberación inmediata de una combinación triple de principios activos farmacéuticos, útil en el tratamiento del síndrome del ovario poliquístico.
MX2022003246A (es) Composiciones de polimero liquido y sistemas para suministro prolongado de peptidos como ingredientes farmaceuticos activos.
EA202092021A1 (ru) Инъекционная композиция
TH159014A (th) สูตรตำรับสิ่งปลูกถ่ายพาลิเพอริโด
UA111566C2 (uk) Фармацевтична композиція пролонгованого вивільнення морфолінію [(5-метил-1н-1,2,4-триазол-3-іл)тіо]ацетату